Efficacy and Safety of Ceftaroline Fosamil in Hospitalized Patients with Community-Acquired Pneumonia in China: Subset Analysis of an International Phase 3 Randomized Controlled Trial

References

• Chen L, Zhou F, Li H, et al. Disease characteristics and management of hospitalised adolescents and adults with community-acquired pneumonia in China: a retrospective multicentre survey. BMJ Open. 2018;8(2):e018709. doi:10.1136/bmjopen-2017-018709
   PubMed Web of Science ®Google Scholar
• Cao B, Huang Y, She DY, et al. Diagnosis and treatment of community-acquired pneumonia in adults: 2016 clinical practice guidelines by the Chinese Thoracic Society, Chinese Medical Association. Clin Respir J. 2018;12(4):1320–1360. doi:10.1111/crj.12674
   PubMed Web of Science ®Google Scholar
• Song J-H, Thamlikitkul V, Hsueh P-R. Clinical and economic burden of community-acquired pneumonia amongst adults in the Asia-Pacific region. Int J Antimicrob Agents. 2011;38(2):108–117. doi:10.1016/j.ijantimicag.2011.02.017
   PubMed Web of Science ®Google Scholar
• Zhao M, Song B, Liu Y, Pu Z, Yu H. Etiological classification and clinical research on community-acquired pneumonia in Yantai, China. Biomedical Res. 2017;28(8):3501–3506.
   Google Scholar
• Zhu YG, Tang XD, Lu YT, Zhang J, Qu JM. Contemporary situation of community-acquired pneumonia in China: a systematic review. J Transl Int Med. 2018;6(1):26–31. doi:10.2478/jtim-2018-0006
   PubMed Web of Science ®Google Scholar
• Marchello C, Dale AP, Thai TN, Han DS, Ebell MH. Prevalence of atypical pathogens in patients with cough and community-acquired pneumonia: a meta-analysis. Ann Fam Med. 2016;14(6):552–566. doi:10.1370/afm.1993
   PubMed Web of Science ®Google Scholar
• Wang H, Liu YL, Chen MJ, et al. [Antimicrobial susceptibility of community-acquired respiratory tract pathogens isolated from adults in China during 2009 and 2010]. Zhonghua Jie He He Hu Xi Za Zhi. 2012;35(2):113–119. Chinese.
   Google Scholar
• Peto L, Nadjm B, Horby P, et al. The bacterial aetiology of adult community-acquired pneumonia in Asia: a systematic review. Trans R Soc Trop Med Hyg. 2014;108(6):326–337. doi:10.1093/trstmh/tru058
   PubMed Web of Science ®Google Scholar
• Zhao C, Zhang F, Wang Z, et al. [Resistance surveillance of major pathogens for adult community-acquired respiratory tract infections in China: a multicenter study 2012]. Zhonghua Jie He He Hu Xi Za Zhi. 2015;38(1):18–22. Chinese.
   Google Scholar
• Liu Y, Chen M, Zhao T, et al. Causative agent distribution and antibiotic therapy assessment among adult patients with community acquired pneumonia in Chinese urban population. BMC Infect Dis. 2009;9:31. doi:10.1186/1471-2334-9-31
   PubMed Web of Science ®Google Scholar
• Zhang X, Wang R, Di X, Liu B, Liu Y. Different microbiological and clinical aspects of lower respiratory tract infections between China and European/American countries. J Thorac Dis. 2014;6(2):134–142. doi:10.3978/j.issn.2072-1439.2014.02.02
   Web of Science ®Google Scholar
• Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections–full version. Clin Microbiol Infect. 2011;17(Suppl 6):E1–59. doi:10.1111/j.1469-0691.2011.03672.x
   PubMed Web of Science ®Google Scholar
• Gupta D, Agarwal R, Aggarwal AN, et al. Guidelines for diagnosis and management of community- and hospital-acquired pneumonia in adults: joint ICS/NCCP(I) recommendations. Lung India. 2012;29(Suppl 2):S27–62. doi:10.4103/0970-2113.99248
   Google Scholar
• Infectious Diseases Society of Taiwan, Taiwan Society of Pulmonary and Critical Medicine, Medical Foundation in Memory of Dr. Deh-Lin Cheng, Foundation of Professor Wei-Chuan Hsieh for Infectious Diseases Research and Education, C. Y. Lee’s Research Foundation for Pediatric Infectious Diseases and Vaccines. Guidelines on antimicrobial therapy of pneumonia in adults in Taiwan, revised 2006. J Microbiol Immunol Infect. 2007;40(3):279–283.
   Google Scholar
• Committee for The Japanese Respiratory Society guidelines for the management of respiratory infections. Guidelines for the management of community acquired pneumonia in adults, revised edition. Respirology. 2006;11(Suppl 3):S79–133. doi:10.1111/j.1440-1843.2006.00937_1.x
   Google Scholar
• Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200(7):e45–e67. doi:10.1164/rccm.201908-1581ST
   PubMed Web of Science ®Google Scholar
• Pfizer. Zinforo 600 mg powder for concentrate for solution for infusion: summary of product characteristics; 2020. Available from: https://www.ema.europa.eu/en/documents/product-information/zinforo-epar-product-information_en.pdf. Accessed 28 April 2021.
   Google Scholar
• Allergan. TEFLARO™ (ceftaroline fosamil) injection for intravenous (IV) use; 2020. Available from: https://www.allergan.com/assets/pdf/teflaro_pi. Accessed 28 April 2021.
   Google Scholar
• File TM Jr, Low DE, Eckburg PB, et al. FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother. 2011;66 Suppl 3:iii19–32. doi:10.1093/jac/dkr096
   Web of Science ®Google Scholar
• Low DE, File TM Jr, Eckburg PB, et al. FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother. 2011;66(Suppl3):iii33–44. doi:10.1093/jac/dkr097
   PubMed Web of Science ®Google Scholar
• Zhong NS, Sun T, Zhuo C, et al. Ceftaroline fosamil versus ceftriaxone for the treatment of Asian patients with community-acquired pneumonia: a randomised, controlled, double-blind, phase 3, non-inferiority with nested superiority trial. Lancet Infect Dis. 2015;15(2):161–171. doi:10.1016/S1473-3099(14)71018-7
   PubMed Web of Science ®Google Scholar
• Taboada M, Melnick D, Iaconis JP, et al. Ceftaroline fosamil versus ceftriaxone for the treatment of community-acquired pneumonia: individual patient data meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2016;71(4):862–870. doi:10.1093/jac/dkv415
   PubMed Web of Science ®Google Scholar
• Li J, Das S, Zhou D, Al-Huniti N. Population pharmacokinetic modeling and probability of target attainment analyses in Asian patients with community-acquired pneumonia treated with ceftaroline fosamil. Clin Pharmacol Drug Dev. 2019;8(5):682–694. doi:10.1002/cpdd.673
   Web of Science ®Google Scholar
• Das S, Li J, Iaconis J, et al. Ceftaroline fosamil doses and breakpoints for Staphylococcus aureus in complicated skin and soft tissue infections. J Antimicrob Chemother. 2019;74:425–431. doi:10.1093/jac/dky439
   PubMed Web of Science ®Google Scholar
• Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336(4):243–250. doi:10.1056/NEJM199701233360402
   PubMed Web of Science ®Google Scholar
• Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58(5):377–382. doi:10.1136/thorax.58.5.377
   PubMed Web of Science ®Google Scholar
• Zhang J, Hu W, Huang Y, Qu J, Infection Assembly of the Chinese Thoracic S. Blind spots of traditional microbiological tests for severe community-acquired pneumonia in adults and availability of nonculture techniques: a Nationwide Survey of Physicians in China. J Infect Dis. 2020;221(Suppl2):S198–S205. doi:10.1093/infdis/jiz636
   Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-Third Informational Supplement M100-S23. Wayne, PA: CLSI; 2013.
   Google Scholar
• Cheng K, Pypstra R, Yan JL, Hammond J. Summary of the safety and tolerability of two treatment regimens of ceftaroline fosamil: 600 mg every 8 h versus 600 mg every 12 h. J Antimicrob Chemother. 2019;74(4):1086–1091. doi:10.1093/jac/dky519
   Web of Science ®Google Scholar
• Lui G, Ip M, Lee N, et al. Role of ‘atypical pathogens’ among adult hospitalized patients with community-acquired pneumonia. Respirology. 2009;14(8):1098–1105. doi:10.1111/j.1440-1843.2009.01637.x
   Web of Science ®Google Scholar
• Huang HH, Zhang YY, Xiu QY, et al. Community-acquired pneumonia in Shanghai, China: microbial etiology and implications for empirical therapy in a prospective study of 389 patients. Eur J Clin Microbiol Infect Dis. 2006;25(6):369–374. doi:10.1007/s10096-006-0146-7
   Web of Science ®Google Scholar
• Yoo KH, Yoo CG, Kim SK, et al. Economic burden and epidemiology of pneumonia in Korean adults aged over 50 years. J Korean Med Sci. 2013;28(6):888–895. doi:10.3346/jkms.2013.28.6.888
   PubMed Web of Science ®Google Scholar
• Tao LL, Hu BJ, He LX, et al. Etiology and antimicrobial resistance of community-acquired pneumonia in adult patients in China. Chin Med J (Engl). 2012;125(17):2967–2972.
   PubMed Web of Science ®Google Scholar
• Bae IG, Stone GG. Activity of ceftaroline against pathogens associated with community-acquired pneumonia collected as part of the AWARE surveillance program, 2015-2016. Diagn Microbiol Infect Dis. 2019;95(3):114843. doi:10.1016/j.diagmicrobio.2019.05.015
   PubMed Web of Science ®Google Scholar
• Brayfield A. Martindale: The Complete Drug Reference. 39th ed. London, UK: Pharmaceutical Press; 2017.
   Google Scholar